Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEOPATTRA coramitug study in ATTR cardiomyopathy
NL-OMON60043Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyloidotic transthyretin cardiomyopathy (ATTR-CM) and heart failure (HF) comparing Coramitug + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Number of occurrences of the composite endpoint of cardiovascular death and recurrent cardiovascular events. Started Apr 2026; status: recruiting.
02
Drugs
coramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)heart failure (HF)
Beyond the preview
Go deeper on NL-OMON60043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60043.